<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="214532">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00293046</url>
  </required_header>
  <id_info>
    <org_study_id>GT-10</org_study_id>
    <nct_id>NCT00293046</nct_id>
  </id_info>
  <brief_title>Assessment of Grazax® Treatment Compliance</brief_title>
  <official_title>A Randomised, Parallel-Group, Open, Controlled Phase III Trial Assessing the Treatment Compliance With GRAZAX® in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ALK-Abelló A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ALK-Abelló A/S</source>
  <brief_summary>
    <textblock>
      This trial is performed to assess whether the Grazax® treatment compliance can be improved
      by use of a compliance device (Memozax®).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">October 2007</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of treatment compliance by recording of drug accountability</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recording of adverse events</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Allergy</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALK Grass tablet - use of compliance device</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Grass pollen induced rhinoconjunctivitis

          -  Males and females, 18-65 years of age

          -  Positive skin prick test

        Exclusion Criteria:

          -  Previous treatment with grass pollen allergen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kim Simonsen, MD</last_name>
    <role>Study Director</role>
    <affiliation>ALK-Abelló A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Allgergie - Ambulatorium Rennweg</name>
      <address>
        <city>Wien</city>
        <zip>1030</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <lastchanged_date>September 29, 2008</lastchanged_date>
  <firstreceived_date>February 16, 2006</firstreceived_date>
  <keyword>Allergy</keyword>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
